Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol.
Abnormal expression of membrane receptors has been previously described in benign adrenocortical neoplasms causing Cushing's syndrome. In particular, we have observed that, in some adreno corticotropic hormone (ACTH)-independent macronodular adrenal hyperplasia tissues, cortisol secretion is controlled by ectopic serotonin(7) (5-HT(7)) receptors. The objective of the present study was to investigate in vitro the effect of serotonin (5-hydroxy tryptamine; 5-HT) on cortisol and renin production by a left adrenocortical carcinoma removed from a 48-year-old female patient with severe Cushing's syndrome and elevated plasma renin levels. Tumor explants were obtained at surgery and processed for immunohistochemistry, in situ hybridization and cell culture studies. 5-HT-like immunoreactivity was observed in mast cells and steroidogenic cells disseminated in the tissue. 5-HT stimulated cortisol release by cultured cells. The stimulatory effect of 5-HT on cortisol secretion was suppressed by the 5-HT(7) receptor antagonist SB269970. In addition, immunohistochemistry showed the occurrence of 5-HT(7) receptor-like immunoreactivity in carcinoma cells. mRNAs encoding renin as well as renin-like immunoreactivity were detected in endothelial and tumor cells. Cell incubation studies revealed that the adrenocortical tissue also released renin. Renin production was inhibited by 5-HT but was not influenced by ACTH and angiotensin II (Ang II). In conclusion, the present report provides the first demonstration of ectopic serotonin receptors, i.e. 5-HT(7) receptors, in an adrenocortical carcinoma. Our results also indicate that 5-HT can influence the secretory activity of malignant adrenocortical tumors in an autocrine/paracrine manner. The effects of 5-HT on adrenocortical tumor cells included a paradoxical inhibitory action on renin production and a stimulatory action on cortisol secretion involving 5-HT(7) receptors.
Louiset
E
E
INSERM U413, EA4310, IFRMP 23, Laboratory of Differentiation and Neuronal and Neuroendocrine Communication, University of Rouen, Mont Saint Aignan 76821, France.
Isvi
K
K
Gasc
J M
JM
Duparc
C
C
Cauliez
B
B
Laquerrière
A
A
Kuhn
J M
JM
Lefebvre
H
H
D000306:Adrenal Cortex Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D018268:Adrenocortical Carcinoma / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D003480:Cushing Syndrome / Q000378:metabolism / Q000473:pathology; D005260:Female; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D006854:Hydrocortisone / Q000235:genetics / Q000378:metabolism*; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology; D011985:Receptors, Serotonin / Q000378:metabolism*; D012083:Renin / Q000235:genetics / Q000378:metabolism*; D012701:Serotonin / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D006728:Hormones; D010636:Phenols; D011985:Receptors, Serotonin; C404922:SB 269970; D013449:Sulfonamides; D014662:Vasoconstrictor Agents; C104425:serotonin 7 receptor; D000804:Angiotensin II; D012701:Serotonin; D000324:Adrenocorticotropic Hormone; D012083:Renin; D006854:Hydrocortisone